Search

Displaying results 2751 - 2760 of 10000 in total
  1. Drug

    Palbociclib

    go.drugbank.com/drugs/DB09073
    ApprovedInvestigational

    [L5867] It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male … It is a second generation cyclin-dependent kinase inhibitor[A176798] selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  2. Drug

    NS-3728

    go.drugbank.com/drugs/DB05835
    Experimental

    NS3728 is an orally active chloride channel blocker for the treatment of cancer.

  3. Drug

    Stiripentol

    go.drugbank.com/drugs/DB09118
    ApprovedInvestigational

    [A250825] However, its clinical efficacy as adjunctive therapy for epilepsies stems from its inhibitory action on CYP enzymes, as stiripentol reduces the degradation of CYP-sensitive antiepileptic drugs

  4. Drug

    MN-246

    go.drugbank.com/drugs/DB05981
    Experimental

    MN-246 is a novel ß3-adrenergic receptor agonist developed for the treatment of urinary incontinence by MediciNova Inc.

  5. Drug

    Damoctocog alfa pegol

    go.drugbank.com/drugs/DB14700
    ApprovedInvestigational

    in patients diagnosed with Haemophilia A. … In order to extend half-lives, techniques such as fusion to protein conjugates (Fc part of IgG1 or albumin), chemical modification (PEGylation), and protein sequence modification have been utilized.

  6. Drug

    Penicillamine

    go.drugbank.com/drugs/DB00859
    ApprovedInvestigational

    Penicillamine is a pharmaceutical of the chelator class. The pharmaceutical form is D-penicillamine, as L-penicillamine is toxic (it inhibits the action of pyridoxine).

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Imatinib

    go.drugbank.com/drugs/DB00619
    ApprovedInvestigational

    Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy". … [A249305] It was deemed a "miracle drug" due to its clinical success, as oncologist Dr.

    Products: IMATINIB AL 100 MG FTA, IMATINIB AL 400 MG FTA
  8. Drug

    Besifloxacin

    go.drugbank.com/drugs/DB06771
    Approved

    Besifloxacin is a fourth generation fluoroquinolone-type opthalmic antibiotic for the treatment of bacterial conjunctivitis. FDA approved on May 28, 2009.

  9. Drug

    Etynodiol

    go.drugbank.com/drugs/DB13866
    Experimental

    Etynodiol (INN), or ethynodiol (BAN) is a steroidal progestin related to norethisterone which was never marketed. … While etynodiol is sometimes used as a synonym for etynodiol diacetate, it usually refers to etynodiol diacetate (see [DB00823]), not etynodiol.

    Categories: Hormonal Contraceptives for Systemic Use
  10. Drug

    Motexafin lutetium

    go.drugbank.com/drugs/DB05296
    Investigational

    Motexafin lutetium (MLu) is a second-generation photosensitizer for photodynamic therapy (PDT) of cancer. It belongs to the family of drugs called metallotexaphyrins. Also called lutetium texaphyrin. … Motexafin lutetium is a pentadentate aromatic metallotexaphyrin with photosensitizing properties.

    Categories: Heterocyclic Compounds with 4 or More Rings